Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome

Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer. Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficiencies. The endpoint of pembrolizumab treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Keating, Matthew, Giscombe, Lisa, Tannous, Toufic, Hartshorn, Kevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745160/
https://www.ncbi.nlm.nih.gov/pubmed/31565451
http://dx.doi.org/10.1155/2019/3847672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745160/
https://www.ncbi.nlm.nih.gov/pubmed/31565451
http://dx.doi.org/10.1155/2019/3847672

Ejemplares similares